X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-06-04 | ITOS | Iteos Therapeutics, Inc. | Detheux Michel | CEO | S - Sale+OE | $10.15 | -156,847 | 135,903 | -54% | -$1,592,520 | |||||
| DM | 2025-06-04 | ITOS | Iteos Therapeutics, Inc. | Hallal David | Dir | S - Sale+OE | $10.15 | -114,682 | 0 | -100% | -$1,164,405 | |||||
2025-06-04 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale | $36.96 | -2,725 | 241,723 | -1% | -$100,716 | ||||||
2025-06-05 | AMGN | Amgen Inc | Khosla Rachna | SVP, Business Development | S - Sale | $289.68 | -1,500 | 8,162 | -16% | -$434,520 | ||||||
2025-06-05 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale | $7.78 | -10,000 | 65,462 | -13% | -$77,800 | ||||||
2025-06-05 | IOVA | Iovance Biotherapeutics, Inc. | Kirby Daniel Gordon | Chief Commercial Officer | P - Purchase | $1.84 | +30,000 | 30,000 | New | +$55,200 | ||||||
2025-06-02 | EXEL | Exelixis, Inc. | Eckhardt Sue Gail | Dir | S - Sale | $42.74 | -18,838 | 21,380 | -47% | -$805,140 | ||||||
2025-06-03 | EXEL | Exelixis, Inc. | Wyszomierski Jack L | Dir | S - Sale | $43.09 | -7,535 | 358,882 | -2% | -$324,683 | ||||||
2025-06-03 | EDIT | Editas Medicine, Inc. | Parison Amy | SVP, CFO | S - Sale | $1.72 | -446 | 17,506 | -2% | -$769 | ||||||
2025-06-03 | EDIT | Editas Medicine, Inc. | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | S - Sale | $1.72 | -726 | 69,519 | -1% | -$1,252 | ||||||
2025-06-03 | EDIT | Editas Medicine, Inc. | O'Neill Gilmore Neil | CEO | S - Sale | $1.72 | -15,192 | 280,282 | -5% | -$26,196 | ||||||
| M | 2025-06-02 | CDTX | Cidara Therapeutics, Inc. | Mineo Chrysa | Dir | P - Purchase | $22.26 | +3,320 | 3,320 | New | +$73,896 | |||||
2025-06-02 | ALEC | Alector, Inc. | Grasso Marc | CFO | S - Sale | $1.34 | -16,488 | 296,072 | -5% | -$22,068 | ||||||
2025-06-02 | ALEC | Alector, Inc. | Kenkare-Mitra Sara | Pres, Head of R, D | S - Sale | $1.34 | -23,890 | 512,252 | -4% | -$31,974 | ||||||
2025-06-02 | ALEC | Alector, Inc. | Rosenthal Arnon | CEO | S - Sale | $1.34 | -52,087 | 6,345,032 | -1% | -$69,713 | ||||||
2025-06-03 | GLUE | Monte Rosa Therapeutics, Inc. | Dunn Edmund | Principal Accounting Officer | S - Sale | $4.45 | -2,062 | 23,732 | -8% | -$9,174 | ||||||
| D | 2025-06-02 | VCEL | Vericel Corp | Hopper Jonathan Mark | Chief Medical Officer | S - Sale+OE | $40.09 | -10,000 | 66,237 | -13% | -$400,900 | |||||
2025-05-30 | TSHA | Taysha Gene Therapies, Inc. | Manning Paul B | 10% | P - Purchase | $2.75 | +750,000 | 25,601,111 | +3% | +$2,062,500 | ||||||
| D | 2025-06-03 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Dir | S - Sale+OE | $49.04 | -5,000 | 0 | -100% | -$245,186 | |||||
| D | 2025-06-03 | KYMR | Kymera Therapeutics, Inc. | Ridloff Elena | Dir | S - Sale+OE | $46.10 | -12,000 | 0 | -100% | -$553,200 | |||||
| D | 2025-06-03 | KYMR | Kymera Therapeutics, Inc. | Mainolfi Nello | CEO | S - Sale+OE | $49.00 | -30,000 | 660,482 | -4% | -$1,470,000 | |||||
| D | 2025-06-03 | KYMR | Kymera Therapeutics, Inc. | Albers Jeffrey W. | Dir | S - Sale+OE | $49.00 | -6,349 | 0 | -100% | -$311,101 | |||||
2025-05-30 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale | $110.42 | -10,000 | 620,268 | -2% | -$1,104,193 | ||||||
| D | 2025-06-02 | VIR | Vir Biotechnology, Inc. | Napolitano Janet | Dir | S - Sale+OE | $5.05 | -3,200 | 16,416 | -16% | -$16,149 | |||||
| D | 2025-05-27 | NKGN | Nkgen Biotech, Inc. | Cfic-2015 Nv Family Investments, LLC | 10% | P - Purchase | $0.13 | +19,669,552 | 21,752,885 | +944% | +$2,500,000 | |||||
2025-05-30 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $2.21 | +100 | 141,766 | 0% | +$221 | ||||||
| D | 2025-05-29 | CRSP | Crispr Therapeutics AG | Patel Naimish | Chief Medical Officer | S - Sale+OE | $35.94 | -3,932 | 6,068 | -39% | -$141,316 | |||||
2025-05-29 | SRRK | Scholar Rock Holding Corp | Flier Jeffrey S. | Dir | S - Sale | $29.73 | -6,075 | 46,342 | -12% | -$180,584 | ||||||
2025-05-29 | SRRK | Scholar Rock Holding Corp | Burow Kristina | Dir | S - Sale | $29.72 | -5,400 | 2,366,782 | 0% | -$160,511 | ||||||
2025-05-29 | SRRK | Scholar Rock Holding Corp | Gilman Michael | Dir | S - Sale | $29.72 | -3,375 | 55,216 | -6% | -$100,304 | ||||||
2025-05-29 | SRRK | Scholar Rock Holding Corp | Brudnick Richard | Dir | S - Sale | $29.72 | -6,075 | 15,057 | -29% | -$180,531 | ||||||
2025-05-29 | SRRK | Scholar Rock Holding Corp | Reed Joshua | Dir | S - Sale | $29.72 | -5,400 | 15,732 | -26% | -$160,463 | ||||||
2025-05-29 | SRRK | Scholar Rock Holding Corp | Vaishnaw Akshay | Pres of R, D | S - Sale | $29.72 | -6,750 | 616,205 | -1% | -$200,612 | ||||||
2025-05-27 | NBIX | Neurocrine Biosciences Inc | Gorman Kevin Charles | Dir | S - Sale | $120.38 | -9,613 | 514,596 | -2% | -$1,157,211 | ||||||
| D | 2025-05-27 | ACLX | Arcellx, Inc. | Gilson Michelle | CFO | S - Sale+OE | $64.14 | -12,235 | 19,776 | -38% | -$784,777 | |||||
2025-05-23 | CHRS | Coherus Biosciences, Inc. | Wahlstrom Mats | Dir | S - Sale | $0.74 | -99,988 | 0 | -100% | -$73,881 | ||||||
2025-05-23 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $27.73 | -839 | 50,191 | -2% | -$23,264 | ||||||
2025-05-22 | DBVT | Dbv Technologies S.A. | Mohideen Pharis | Chief Medical Officer | S - Sale | $1.84 | -397 | 110,113 | 0% | -$730 | ||||||
2025-05-23 | IOVA | Iovance Biotherapeutics, Inc. | Puri Raj K. | Chief Regulatory Officer | P - Purchase | $1.74 | +5,600 | 206,852 | +3% | +$9,743 | ||||||
2025-05-27 | CMPX | Compass Therapeutics, Inc. | Schuetz Thomas J. | CEO | P - Purchase | $2.11 | +10,000 | 6,480,825 | 0% | +$21,100 | ||||||
| DM | 2025-05-21 | ADMA | Adma Biologics, Inc. | Guiheen Lawrence P. | Dir | S - Sale+OE | $20.29 | -9,000 | 165,820 | -5% | -$182,636 | |||||
| M | 2025-05-21 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | Former 10% Owner | P - Purchase | $2.06 | +3,500 | 394,607 | +1% | +$7,200 | |||||
2025-05-23 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | S - Sale | $29.30 | -2,575 | 66,420 | -4% | -$75,436 | ||||||
2025-05-21 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $29.75 | -531 | 105,318 | -1% | -$15,796 | ||||||
2025-05-21 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $29.75 | -632 | 128,748 | 0% | -$18,800 | ||||||
2025-05-21 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $29.75 | -1,877 | 240,783 | -1% | -$55,835 | ||||||
| D | 2025-05-21 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $29.75 | -2,802 | 649,630 | 0% | -$83,351 | |||||
2025-05-21 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $29.75 | -242 | 51,030 | 0% | -$7,199 | ||||||
2025-05-21 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $29.75 | -936 | 106,018 | -1% | -$27,843 | ||||||
| D | 2025-05-22 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Commercial Officer | S - Sale+OE | $107.52 | -28,000 | 121,152 | -19% | -$3,010,564 | |||||
2025-05-20 | REPL | Replimune Group, Inc. | Astley-Sparke Philip | Dir | S - Sale | $8.06 | -32,279 | 1,405,071 | -2% | -$260,169 | ||||||
2025-05-20 | REPL | Replimune Group, Inc. | Xynos Konstantinos | Chief Medical Officer | S - Sale | $8.06 | -7,952 | 146,933 | -5% | -$64,093 | ||||||
2025-05-20 | REPL | Replimune Group, Inc. | Schwendenman Andrew | Chief Accounting Officer | S - Sale | $8.05 | -3,287 | 68,284 | -5% | -$26,460 | ||||||
2025-05-20 | REPL | Replimune Group, Inc. | Patel Sushil | CEO | S - Sale | $8.06 | -25,105 | 343,576 | -7% | -$202,346 | ||||||
2025-05-20 | REPL | Replimune Group, Inc. | Hill Emily Luisa | CFO | S - Sale | $8.05 | -2,535 | 143,522 | -2% | -$20,407 | ||||||
2025-05-20 | REPL | Replimune Group, Inc. | Sarchi Christopher | Chief Commercial Officer | S - Sale | $8.05 | -3,749 | 128,296 | -3% | -$30,179 | ||||||
2025-05-20 | EXEL | Exelixis, Inc. | Haley Patrick J. | EVP, Commercial | S - Sale | $44.06 | -34,387 | 446,259 | -7% | -$1,515,091 | ||||||
2025-05-21 | EXEL | Exelixis, Inc. | Heyman Tomas J. | Dir | S - Sale | $44.29 | -4,544 | 32,470 | -12% | -$201,254 | ||||||
| M | 2025-05-20 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $2.02 | +2,300 | 141,666 | +2% | +$4,651 | |||||
2025-05-20 | PRME | Prime Medicine, Inc. | Brudnick Richard | Chief Business Officer | P - Purchase | $1.19 | +20,000 | 20,000 | New | +$23,790 | ||||||
2025-05-21 | PRME | Prime Medicine, Inc. | Lee Ann L. | Chief Technical Officer | P - Purchase | $1.13 | +100,000 | 100,000 | New | +$113,000 | ||||||
2025-05-21 | PRME | Prime Medicine, Inc. | Reine Allan | CEO | P - Purchase | $1.18 | +125,000 | 125,000 | New | +$147,150 | ||||||
| D | 2025-05-21 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $28.00 | -1,000 | 0 | -100% | -$28,000 | |||||
| D | 2025-05-21 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale+OE | $7.59 | -346 | 9,216 | -4% | -$2,624 | |||||
| D | 2025-05-21 | DNA | Ginkgo Bioworks Holdings, Inc. | Dmytruk Mark E. | See Remarks | S - Sale+OE | $7.59 | -706 | 46,226 | -2% | -$5,355 | |||||
| M | 2025-05-19 | TCRX | Tscan Therapeutics, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $1.20 | +2,588,794 | 14,692,282 | +21% | +$3,106,553 | |||||
| D | 2025-05-20 | ACLX | Arcellx, Inc. | Patel Kavita | Dir | S - Sale+OE | $58.43 | -1,500 | 0 | -100% | -$87,645 | |||||
| A | 2025-05-16 | ADPT | Adaptive Biotechnologies Corp | Piskel Kyle | CFO | S - Sale | $8.89 | -1,929 | 269,581 | -1% | -$17,149 | |||||
| D | 2025-05-16 | AURA | Aura Biosciences, Inc. | Johnson David Michael | Dir | P - Purchase | $4.90 | +20,000 | 455,839 | +5% | +$98,000 | |||||
| D | 2025-05-16 | AURA | Aura Biosciences, Inc. | Gibney Anthony S | See Remarks | P - Purchase | $4.90 | +50,000 | 56,933 | +721% | +$245,000 | |||||
| D | 2025-05-16 | AURA | Aura Biosciences, Inc. | Gibney Anthony S | See Remarks | S - Sale+OE | $5.15 | -1,519 | 56,933 | -3% | -$7,823 | |||||
2025-05-16 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | CEO | S - Sale | $2.77 | -1,074 | 221,173 | 0% | -$2,979 | ||||||
2025-05-16 | LXEO | Lexeo Therapeutics, Inc. | Adler Eric | Chief Medical Officer | S - Sale | $2.77 | -585 | 67,681 | -1% | -$1,623 | ||||||
2025-05-16 | LXEO | Lexeo Therapeutics, Inc. | Robertson Jenny | GC | S - Sale | $2.77 | -521 | 63,098 | -1% | -$1,445 | ||||||
2025-05-16 | LXEO | Lexeo Therapeutics, Inc. | See Tai Sandi | Chief Development Officer | S - Sale | $2.77 | -367 | 59,242 | -1% | -$1,018 | ||||||
2025-05-16 | ATRA | Atara Biotherapeutics, Inc. | Grant-Huerta Yanina | Chief Accounting Officer | S - Sale | $6.76 | -2,218 | 37,067 | -6% | -$15,000 | ||||||
2025-05-16 | ATRA | Atara Biotherapeutics, Inc. | Nguyen Anhco | Pres, CEO | S - Sale | $6.76 | -3,276 | 70,847 | -4% | -$22,156 | ||||||
2025-05-16 | XFOR | X4 Pharmaceuticals, Inc | Baldry Mark | Chief Commercial Officer | P - Purchase | $2.48 | +1,032 | 25,337 | +4% | +$2,561 | ||||||
2025-05-16 | IPSC | Century Therapeutics, Inc. | Pfeiffenberger Brent | Pres, CEO | S - Sale | $0.55 | -29,552 | 1,682,258 | -2% | -$16,135 | ||||||
2025-05-19 | BIIB | Biogen Inc. | Singhal Priya | Head of Development | S - Sale | $126.25 | -3,806 | 5,427 | -41% | -$480,508 | ||||||
2025-05-19 | ABP | Abpro Holdings, Inc. | Suk Jin Wook (Miles) | CEO, COB | P - Purchase | $0.26 | +16,200 | 146,477 | +12% | +$4,212 | ||||||
2025-05-16 | ADPT | Adaptive Biotechnologies Corp | Piskel Kyle | CFO | S - Sale | $8.89 | -1,929 | 277,396 | -1% | -$17,149 | ||||||
2025-05-19 | VXRT | Vaxart, Inc. | Lo Steven | Pres, Chief Exec Officer | P - Purchase | $0.49 | +100,000 | 100,000 | New | +$49,000 | ||||||
| M | 2025-05-16 | FENC | Fennec Pharmaceuticals Inc. | Hackman Jeffrey S. | CEO | P - Purchase | $6.97 | +15,000 | 15,000 | New | +$104,602 | |||||
2025-05-16 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale | $6.78 | -16,667 | 70,254 | -19% | -$113,002 | ||||||
| A | 2025-05-14 | TARA | Protara Therapeutics, Inc. | Levy Richard S | Dir | P - Purchase | $3.19 | +20,000 | 51,000 | +65% | +$63,800 | |||||
| D | 2025-05-15 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres, CEO | S - Sale+OE | $19.45 | -21,000 | 3,774,233 | -1% | -$408,450 | |||||
| D | 2025-05-16 | EXEL | Exelixis, Inc. | Poste George | Dir | S - Sale+OE | $45.99 | -20,634 | 169,020 | -11% | -$948,958 | |||||
| D | 2025-05-16 | EXEL | Exelixis, Inc. | Senner Christopher J. | EVP, CFO | S - Sale+OE | $46.00 | -100,000 | 970,565 | -9% | -$4,600,000 | |||||
| D | 2025-05-15 | EXEL | Exelixis, Inc. | Papadopoulos Stelios | Dir | S - Sale+OE | $44.35 | -36,508 | 1,279,416 | -3% | -$1,619,130 | |||||
2025-05-15 | EXEL | Exelixis, Inc. | Hessekiel Jeffrey | EVP, GC | S - Sale | $46.18 | -25,000 | 694,395 | -3% | -$1,154,500 | ||||||
| DM | 2025-05-14 | EXEL | Exelixis, Inc. | Haley Patrick J. | EVP, Commercial | S - Sale+OE | $47.58 | -136,383 | 480,646 | -22% | -$6,488,503 | |||||
| D | 2025-05-16 | EXEL | Exelixis, Inc. | Peterson Amy C. | EVP Prod Dev, Med Aff, CMO | S - Sale+OE | $45.47 | -72,776 | 465,393 | -14% | -$3,309,125 | |||||
2025-05-16 | TNYA | Tenaya Therapeutics, Inc. | Higa Tomohiro | SVP, Finance | S - Sale | $0.44 | -1,390 | 98,300 | -1% | -$615 | ||||||
2025-05-16 | TNYA | Tenaya Therapeutics, Inc. | Tingley Whittemore | Chief Medical Officer | S - Sale | $0.44 | -2,937 | 171,856 | -2% | -$1,300 | ||||||
2025-05-16 | TNYA | Tenaya Therapeutics, Inc. | Ali Faraz | CEO | S - Sale | $0.44 | -3,189 | 317,325 | -1% | -$1,412 | ||||||
| M | 2025-05-14 | ITOS | Iteos Therapeutics, Inc. | Ecor1 Capital, LLC | 10% | P - Purchase | $7.80 | +4,958,978 | 10,688,978 | +87% | +$38,685,562 | |||||
| M | 2025-05-14 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $2.57 | +400 | 139,366 | 0% | +$1,028 | |||||
2025-05-15 | ADVM | Adverum Biotechnologies, Inc. | Soparkar Peter | COO | S - Sale | $2.00 | -2,960 | 39,154 | -7% | -$5,920 | ||||||
2025-05-15 | ADVM | Adverum Biotechnologies, Inc. | Seyedkazemi Setareh | Chief Development Officer | S - Sale | $2.00 | -924 | 13,768 | -6% | -$1,848 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |